CalciMedica's lead candidate, Auxora, showed promising protective effects in AKI, with trial rationale published in the American Journal of Nephrology.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CalciMedica's lead candidate, Auxora, showed promising protective effects in AKI, with trial rationale published in the American Journal of Nephrology.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CalciMedica (United States)
company in La Jolla, United States
Nothing else this week.
-
Glenn Chertow
researcher
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet